CrossRef Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden Ming-Cheng Guan, Na Li, Qian Ding, Di Sun, Hao Li, Mei Yang, Lei Hong, Hong Zhu Frontiers in Immunology .2025;[Epub] CrossRef Visittovisit variability of inflammationimmunity indices and prognosis in hepatocellular carcinoma Qiajun Du, Youli Zhao, Jing Yang, Yongxin Yang BMC Gastroenterology .2025;[Epub] CrossRef Biomimetic Nanomedicine for SenescenceModulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji Advanced Science .2025;[Epub] CrossRef Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels Kuan-Jung Huang, Chun-Ting Ho, Pei-Chang Lee, San-Chi Chen, Chien-An Liu, Shu-Cheng Chou, I-Cheng Lee, Yi-Hsiang Huang, Jiing-Chyuan Luo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su Journal of the Chinese Medical Association .2025
Tirzepatide can: Currently, tirzepatide is only available as a once-a-week injectable medication
10.1016/j.intimp.2017.10.020 [DOI] [PubMed] [Google Scholar] Wang Y., Wu S., Zhu X., Zhang L., Deng J., Li F., et al
What are the key benefits of AHK-Cu in this liquid format
